Publicaciones en colaboración con investigadores/as de Johns Hopkins University School of Medicine (13)

2022

  1. Interplay Between Duration of Androgen Deprivation Therapy and External Beam Radiotherapy With or Without a Brachytherapy Boost for Optimal Treatment of High-risk Prostate Cancer A Patient-Level Data Analysis of 3 Cohorts

    JAMA Oncology, Vol. 8, Núm. 3

2021

  1. Comparison of Multimodal Therapies and Outcomes among Patients with High-Risk Prostate Cancer with Adverse Clinicopathologic Features

    JAMA Network Open, Vol. 4, Núm. 7

  2. Patterns of Clinical Progression in Radiorecurrent High-risk Prostate Cancer[Formula presented]

    European Urology, Vol. 80, Núm. 2, pp. 142-146

  3. Performance of a Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography-Derived Risk-Stratification Tool for High-risk and Very High-risk Prostate Cancer

    JAMA Network Open, Vol. 4, Núm. 12, pp. E2138550

2019

  1. Adjuvant chemoradiation in pancreatic cancer: Impact of radiotherapy dose on survival

    BMC Cancer, Vol. 19, Núm. 1

  2. Prognostic Impact of Presurgical CA19-9 Level in Pancreatic Adenocarcinoma: A Pooled Analysis

    Translational Oncology, Vol. 12, Núm. 1, pp. 1-7

  3. The oncolytic virus Delta-24-RGD elicits an antitumor effect in pediatric glioma and DIPG mouse models

    Nature Communications, Vol. 10, Núm. 1

2018

  1. OV21/PETROC: A randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Annals of Oncology, Vol. 29, Núm. 2, pp. 431-438

  2. OV21/PETROC: A randomized gynecologic cancer intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer

    Obstetrical and Gynecological Survey

2017

  1. Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab

    Cell, Vol. 171, Núm. 4, pp. 934-949.e15

2015

  1. Adjuvant chemoradiation in pancreatic cancer: A pooled analysis in elderly (≥75 years) patients

    Anticancer Research, Vol. 35, Núm. 6, pp. 3441-3446

  2. Organoid models of human and mouse ductal pancreatic cancer

    Cell, Vol. 160, Núm. 1-2, pp. 324-338

2014

  1. Multi-institutional pooled analysis on adjuvant chemoradiation in pancreatic cancer

    International Journal of Radiation Oncology Biology Physics, Vol. 90, Núm. 4, pp. 911-917